At the William Harvey Research Institute (WHRI) we conduct innovative, world-leading research in the fields of cardiovascular, endocrine and inflammation science.
As part of Barts and The London School of Medicine and Dentistry and Queen Mary University of London we are one of the largest multidisciplinary pharmacological institutes in Europe with over 530 clinicians and scientists from 45 countries. Our innovative research environment and close collaboration with Barts Health NHS Trust and healthcare partners across East London gives us a unique opportunity to translate and extend basic and clinical research into therapeutics that benefit the local community and beyond.
In the 2014 Research Excellence Framework (REF) 90% of our research focused on therapeutic innovation in cardiovascular disease, inflammation and endocrinology, and was rated as world-leading or internationally excellent.
In cardiovascular research our discoveries have been published in Nature Journals, enabled new therapies and are repurposing opportunities for unmet need.
Using the translational platform of our successive NIHR Barts Biomedical Research Centre we have created the £400M Barts Heart Centre where we developed and implemented NICE Guidance for hypertension (NICE 2011).
In inflammation research, our high-impact discoveries in leukocyte migration, annexin and invention of new molecules targeting melanocortin are published in top journals and have been commercialised.
In endocrine research, our genomic discoveries in familial acromegaly have allowed us to stratify those who would benefit from early therapy avoiding shortened lives.
With an EU Cofund (€6M), EU PhD scheme (€2.9M), BHF PhD and MRC MRes schemes we created the WHRI Translational Academy for Therapeutic Innovation to train future pharmacologists across the world.